Palvella Therapeutics, Inc. Costs and Expenses
Palvella Therapeutics, Inc. (PVLA) reported Costs and Expenses of $3.69 million for the 3-month period ending 2015-06-30, per its 10-Q filed 2015-08-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2015-08-13
- Palvella Therapeutics, Inc. costs and expenses for the quarter ending 2015-06-30 was $3.69M, a 6.53% increase year-over-year.
- Palvella Therapeutics, Inc. costs and expenses for the quarter ending 2015-03-31 was $3.92M, a 91.72% increase year-over-year.
- Palvella Therapeutics, Inc. costs and expenses for the quarter ending 2014-06-30 was $3.47M.
- Palvella Therapeutics, Inc. costs and expenses for the quarter ending 2014-03-31 was $2.04M.
- Palvella Therapeutics, Inc. costs and expenses for fiscal 2014 was $12.56M, a 5.81% increase from fiscal 2013.
- Palvella Therapeutics, Inc. costs and expenses for fiscal 2013 was $11.87M.
| Period end | Costs and Expenses 3 month | Costs and Expenses 6 month | Costs and Expenses 12 month |
|---|---|---|---|
| 2015-06-30 | $3.69M 10-Q · filed 2015-08-13 | $7.61M 10-Q · filed 2015-08-13 | |
| 2015-03-31 | $3.92M 10-Q · filed 2015-05-14 | ||
| 2014-12-31 | $12.56M 10-K · filed 2015-03-30 | ||
| 2014-06-30 | $3.47M 10-Q · filed 2015-08-13 | $5.51M 10-Q · filed 2015-08-13 | |
| 2014-03-31 | $2.04M 10-Q · filed 2015-05-14 | ||
| 2013-12-31 | $11.87M 10-K · filed 2015-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |